AustralieFrV1, Main, Exploration, bibRecord, 004D28

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Identifieur interne : 004D28 ( Main/Exploration ); précédent : 004D27; suivant : 004D29

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Auteurs : A. M. Evens [États-Unis] ; S. Choquet [France] ; A. R. Kroll-Desrosiers [États-Unis] ; D. Jagadeesh [États-Unis] ; S. M. Smith [États-Unis] ; F. Morschhauser [France] ; V. Leblond [France] ; R. Roy [États-Unis] ; B. Barton [États-Unis] ; L. I. Gordon [États-Unis] ; M. K. Gandhi [Australie] ; D. Dierickx [Belgique] ; D. Schiff [États-Unis] ; T. M. Habermann [États-Unis] ; R. Trappe [Allemagne]

Source :

American journal of transplantation : (Print) [ 1600-6135 ] ; 2013.

RBID : Pascal:13-0235169

Descripteurs français

Pascal (Inist)
- Syndrome lymphoprolifératif posttransplantation, Primaire, Système nerveux central, Syndrome lymphoprolifératif, International, Monde, Lymphome, Compte rendu, Etude cas, Rituximab, Pronostic, Immunodépresseur, Immunothérapie, Anticorps monoclonal, Anticancéreux, Immunomodulateur, Traitement, Antigène CD20, Hémopathie maligne lymphoïde.

English descriptors

KwdEn :
- Antineoplastic agent, Case study, Central nervous system, Immunomodulator, Immunosuppressive agent, Immunotherapy, International, Lymphoid neoplasm, Lymphoma, Lymphoproliferative syndrome, Monoclonal antibody, Posttransplant lymphoproliferative disorder, Primary, Prognosis, Report, Rituximab, Treatment, World.

Abstract

We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000953
to stream PascalFrancis, to step Curation: 005523
to stream PascalFrancis, to step Checkpoint: 000704
to stream Main, to step Merge: 004E78
to stream Main, to step Curation: 004D28

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</title>
<author><name sortKey="Evens, A M" sort="Evens, A M" uniqKey="Evens A" first="A. M." last="Evens">A. M. Evens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Worcester, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Choquet, S" sort="Choquet, S" uniqKey="Choquet S" first="S." last="Choquet">S. Choquet</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kroll Desrosiers, A R" sort="Kroll Desrosiers, A R" uniqKey="Kroll Desrosiers A" first="A. R." last="Kroll-Desrosiers">A. R. Kroll-Desrosiers</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Amherst (Massachusetts)</settlement>
<region type="state">Massachusetts</region>
</placeName>
<orgName type="university">Université du Massachusetts</orgName>
</affiliation>
</author>
<author><name sortKey="Jagadeesh, D" sort="Jagadeesh, D" uniqKey="Jagadeesh D" first="D." last="Jagadeesh">D. Jagadeesh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Worcester, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smith, S M" sort="Smith, S M" uniqKey="Smith S" first="S. M." last="Smith">S. M. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, IL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leblond, V" sort="Leblond, V" uniqKey="Leblond V" first="V." last="Leblond">V. Leblond</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roy, R" sort="Roy, R" uniqKey="Roy R" first="R." last="Roy">R. Roy</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, IL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barton, B" sort="Barton, B" uniqKey="Barton B" first="B." last="Barton">B. Barton</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Amherst (Massachusetts)</settlement>
<region type="state">Massachusetts</region>
</placeName>
<orgName type="university">Université du Massachusetts</orgName>
</affiliation>
</author>
<author><name sortKey="Gordon, L I" sort="Gordon, L I" uniqKey="Gordon L" first="L. I." last="Gordon">L. I. Gordon</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, IL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gandhi, M K" sort="Gandhi, M K" uniqKey="Gandhi M" first="M. K." last="Gandhi">M. K. Gandhi</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Princess Alexandra Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dierickx, D" sort="Dierickx, D" uniqKey="Dierickx D" first="D." last="Dierickx">D. Dierickx</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schiff, D" sort="Schiff, D" uniqKey="Schiff D" first="D." last="Schiff">D. Schiff</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Charlottesville, VA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Habermann, T M" sort="Habermann, T M" uniqKey="Habermann T" first="T. M." last="Habermann">T. M. Habermann</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rochester, MN</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trappe, R" sort="Trappe, R" uniqKey="Trappe R" first="R." last="Trappe">R. Trappe</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0235169</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0235169 INIST</idno>
<idno type="RBID">Pascal:13-0235169</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000953</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005523</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000704</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000704</idno>
<idno type="wicri:doubleKey">1600-6135:2013:Evens A:primary:cns:posttransplant</idno>
<idno type="wicri:Area/Main/Merge">004E78</idno>
<idno type="wicri:Area/Main/Curation">004D28</idno>
<idno type="wicri:Area/Main/Exploration">004D28</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</title>
<author><name sortKey="Evens, A M" sort="Evens, A M" uniqKey="Evens A" first="A. M." last="Evens">A. M. Evens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Worcester, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Choquet, S" sort="Choquet, S" uniqKey="Choquet S" first="S." last="Choquet">S. Choquet</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kroll Desrosiers, A R" sort="Kroll Desrosiers, A R" uniqKey="Kroll Desrosiers A" first="A. R." last="Kroll-Desrosiers">A. R. Kroll-Desrosiers</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Amherst (Massachusetts)</settlement>
<region type="state">Massachusetts</region>
</placeName>
<orgName type="university">Université du Massachusetts</orgName>
</affiliation>
</author>
<author><name sortKey="Jagadeesh, D" sort="Jagadeesh, D" uniqKey="Jagadeesh D" first="D." last="Jagadeesh">D. Jagadeesh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Worcester, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smith, S M" sort="Smith, S M" uniqKey="Smith S" first="S. M." last="Smith">S. M. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, IL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leblond, V" sort="Leblond, V" uniqKey="Leblond V" first="V." last="Leblond">V. Leblond</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roy, R" sort="Roy, R" uniqKey="Roy R" first="R." last="Roy">R. Roy</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, IL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barton, B" sort="Barton, B" uniqKey="Barton B" first="B." last="Barton">B. Barton</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Amherst (Massachusetts)</settlement>
<region type="state">Massachusetts</region>
</placeName>
<orgName type="university">Université du Massachusetts</orgName>
</affiliation>
</author>
<author><name sortKey="Gordon, L I" sort="Gordon, L I" uniqKey="Gordon L" first="L. I." last="Gordon">L. I. Gordon</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, IL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gandhi, M K" sort="Gandhi, M K" uniqKey="Gandhi M" first="M. K." last="Gandhi">M. K. Gandhi</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Princess Alexandra Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dierickx, D" sort="Dierickx, D" uniqKey="Dierickx D" first="D." last="Dierickx">D. Dierickx</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schiff, D" sort="Schiff, D" uniqKey="Schiff D" first="D." last="Schiff">D. Schiff</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Charlottesville, VA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Habermann, T M" sort="Habermann, T M" uniqKey="Habermann T" first="T. M." last="Habermann">T. M. Habermann</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rochester, MN</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trappe, R" sort="Trappe, R" uniqKey="Trappe R" first="R." last="Trappe">R. Trappe</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">American journal of transplantation : (Print)</title>
<title level="j" type="abbreviated">Am. j. transplant. : (Print)</title>
<idno type="ISSN">1600-6135</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">American journal of transplantation : (Print)</title>
<title level="j" type="abbreviated">Am. j. transplant. : (Print)</title>
<idno type="ISSN">1600-6135</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Case study</term>
<term>Central nervous system</term>
<term>Immunomodulator</term>
<term>Immunosuppressive agent</term>
<term>Immunotherapy</term>
<term>International</term>
<term>Lymphoid neoplasm</term>
<term>Lymphoma</term>
<term>Lymphoproliferative syndrome</term>
<term>Monoclonal antibody</term>
<term>Posttransplant lymphoproliferative disorder</term>
<term>Primary</term>
<term>Prognosis</term>
<term>Report</term>
<term>Rituximab</term>
<term>Treatment</term>
<term>World</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome lymphoprolifératif posttransplantation</term>
<term>Primaire</term>
<term>Système nerveux central</term>
<term>Syndrome lymphoprolifératif</term>
<term>International</term>
<term>Monde</term>
<term>Lymphome</term>
<term>Compte rendu</term>
<term>Etude cas</term>
<term>Rituximab</term>
<term>Pronostic</term>
<term>Immunodépresseur</term>
<term>Immunothérapie</term>
<term>Anticorps monoclonal</term>
<term>Anticancéreux</term>
<term>Immunomodulateur</term>
<term>Traitement</term>
<term>Antigène CD20</term>
<term>Hémopathie maligne lymphoïde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
<li>Schleswig-Holstein</li>
<li>Île-de-France</li>
</region>
<settlement><li>Amherst (Massachusetts)</li>
<li>Kiel</li>
<li>Paris</li>
</settlement>
<orgName><li>Université du Massachusetts</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Evens, A M" sort="Evens, A M" uniqKey="Evens A" first="A. M." last="Evens">A. M. Evens</name>
</noRegion>
<name sortKey="Barton, B" sort="Barton, B" uniqKey="Barton B" first="B." last="Barton">B. Barton</name>
<name sortKey="Gordon, L I" sort="Gordon, L I" uniqKey="Gordon L" first="L. I." last="Gordon">L. I. Gordon</name>
<name sortKey="Habermann, T M" sort="Habermann, T M" uniqKey="Habermann T" first="T. M." last="Habermann">T. M. Habermann</name>
<name sortKey="Jagadeesh, D" sort="Jagadeesh, D" uniqKey="Jagadeesh D" first="D." last="Jagadeesh">D. Jagadeesh</name>
<name sortKey="Kroll Desrosiers, A R" sort="Kroll Desrosiers, A R" uniqKey="Kroll Desrosiers A" first="A. R." last="Kroll-Desrosiers">A. R. Kroll-Desrosiers</name>
<name sortKey="Roy, R" sort="Roy, R" uniqKey="Roy R" first="R." last="Roy">R. Roy</name>
<name sortKey="Schiff, D" sort="Schiff, D" uniqKey="Schiff D" first="D." last="Schiff">D. Schiff</name>
<name sortKey="Smith, S M" sort="Smith, S M" uniqKey="Smith S" first="S. M." last="Smith">S. M. Smith</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Choquet, S" sort="Choquet, S" uniqKey="Choquet S" first="S." last="Choquet">S. Choquet</name>
</region>
<name sortKey="Leblond, V" sort="Leblond, V" uniqKey="Leblond V" first="V." last="Leblond">V. Leblond</name>
<name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name>
</country>
<country name="Australie"><noRegion><name sortKey="Gandhi, M K" sort="Gandhi, M K" uniqKey="Gandhi M" first="M. K." last="Gandhi">M. K. Gandhi</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Dierickx, D" sort="Dierickx, D" uniqKey="Dierickx D" first="D." last="Dierickx">D. Dierickx</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Schleswig-Holstein"><name sortKey="Trappe, R" sort="Trappe, R" uniqKey="Trappe R" first="R." last="Trappe">R. Trappe</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D28 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D28 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:13-0235169
   |texte=   Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri